All News

Dr. Joshua Sabari spoke with advocate Chris Conneran on his journey from caregiver to champion for KRAS-mutant cancer patients and families.

The changing seasons offer a profound metaphor for the circle of life, an idea that resonates deeply with me.

Lutathera demonstrated antitumor activity in patients with metastatic bronchopulmonary neuroendocrine tumors.

For patients with MET exon 14-altered NSCLC, Tepmetko was associated with frequent side effects, although the safety profile is considered manageable.

As the prostate cancer treatment landscape continues to evolve, understanding the risks and benefits of each approach is critical for patients.

Receiving a “Stand Up to Cancer Day” email gave me the strength to support a friend through her darkest cancer days.

Dr. Josh Sabari and Max Doppelt explore challenges in trial enrollment and the potential of emerging therapies to offer hope for patients diagnosed today.

This guide for newly diagnosed patients provides key information to help you understand your options and have informed conversations with your oncologist.

When I think about standing up to cancer, I cannot separate the words from my own story.

For patients with advanced non-small cell lung cancer who progressed on two or more prior regimens, THIO with Libtayo elicited positive responses.

Dr. Thomas Jankowski explained that THIO, a telomerase inhibitor, is being studied with Libtayo to help overcome resistance in advanced lung cancer.

This guide is designed to help you understand liver cancer and equip you with the right questions to ask your medical team.

Choosing the right health insurance plan during Open Enrollment can feel overwhelming, but it doesn’t have to be.

Advances are reshaping treatment for small cell lung cancer, with immunotherapy and emerging options offering hope for longer survival and potential cures.

Susan G. Komen is marking a significant milestone in the effort to improve care and outcomes for people facing inflammatory breast cancer (IBC).

As a 12-year pancreatic cancer survivor, I share my journey through diagnosis, treatment and survival, hoping my story inspires others to act beyond slogans.

Perioperative immunotherapy for the treatment of non-small cell lung cancer is starting to exhibit survival benefits among patients, research has shown.

The FDA has accepted a new drug application for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.

Chemotherapy can trigger early menopause, while strategies and new data on pausing therapy may help women protect fertility and plan pregnancy.

Living with follicular lymphoma, I’ve learned many assumptions about cancer, remission and treatment side effects don’t reflect the reality I face.

This issue of CURE highlights personal stories and expert insights, from living with multiple diagnoses to self-advocacy, nutrition and survivorship care.

Over the past 20 years, there have been dramatic advances in treatment options for people diagnosed with non-small cell lung cancer

When my daughter was diagnosed with breast cancer at 27, I watched her show courage through every treatment, side effect and moment of resolve.

For patients with HR+, HER2- early breast cancer, MammaPrint may predict distant recurrence-free interval prognosis and chemotherapy benefit.

LiveLung invites the Pittsburgh community to its monthly educational meeting.

The FDA has granted fast track designation to the cancer vaccine GLSI-100 for patients with HLA-A*02-positive and HER2-positive breast cancer.

CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.

The FDA has approved Inlexzo for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.